Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologyBCBS Vermont Tumor Treating Fields Coverage | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of VermontPolicy 1.01.VT29

    Tumor Treatment Fields for CNS Cancers Corporate Medical Policy

    Customize your policy alerts

    Sign up for bcbsvermont Policy 1.01.VT29 alerts

    Get alerted when Policy 1.01.VT29 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of tumor treating fields therapy for specified central nervous system cancers, including when the therapy may be medically necessary and when it is investigational. It applies to providers treating Blue Cross Blue Shield of Vermont members, subject to the member’s contract and applicable benefit requirements.

    Policy Summary
    PayerBlue Cross Blue Shield of Vermont
    PolicyTumor Treatment Fields for CNS Cancers
    Policy CodePolicy 1.01.VT29
    Change TypeAdministrative/reference update
    Effective DateFeb 1, 2027
    Last ReviewOct 1, 2026
    Next Review DateSep 1, 2027
    Key ActionSubmit a complete authorization request supporting the applicable medical-necessity criteria before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4CNS tumor types with potentially medically necessary coverage
    2Medical-necessity treatment situations
    2HCPCS codes listed in the coding table
    All other indicationsInvestigational status

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    When Tumor Treating Fields May Be Covered

    Medically Necessary Indications

    Tumor treating fields therapy may be considered medically necessary when either of the following treatment situations applies.

    Covered treatment situations

    • Progressive or recurrent disease after prior treatment: Use as an alternative to standard chemotherapy for progressive or recurrent glioblastoma multiforme, anaplastic oligodendroglioma, anaplastic astrocytoma, or anaplastic gliomas after initial or repeat treatment with surgery, radiotherapy, and/or chemotherapy, when the disease is unresectable or resection is not recommended.
    • Adjuvant treatment for supratentorial GBM: Use as adjuvant treatment to standard therapy in a patient with supratentorial disease and glioblastoma multiforme following initial treatment with surgery, radiotherapy, and/or chemotherapy.

    Tumor treating fields therapy is a noninvasive technology delivered in outpatient settings and at home using electrical fields. Patients reapply the transducer arrays at home after receiving initial instruction. This policy addresses its use primarily for glioblastoma and selected anaplastic gliomas; indications outside the covered situations are considered investigational.

    Treatment Setting Criteria

    Salvage Therapy Criteria

    Covered when all of the following are met:

    Progressive or recurrent disease: The disease is progressive or recurrent after initial or repeat treatment with surgery, radiotherapy, and/or chemotherapy, and is unresectable or resection is not recommended.

    Tumor treating fields therapy is used as an alternative to standard chemotherapy.

    Adjuvant Therapy Criteria

    Covered when all of the following are met:

    Adjuvant post-initial therapy: The patient has supratentorial glioblastoma multiforme following initial treatment with surgery, radiotherapy, and/or chemotherapy.

    Tumor treating fields therapy is used as an adjuvant to standard therapy.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    A4555Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only.
    E0766Electrical stimulation device used for cancer treatment, includes all accessories, any type.

    Authorization and Administrative Requirements

    Prior Authorization

    Conditional Prior Approval for Replacement Electrode/Transducer

    Obtain conditional prior approval for HCPCS A4555 when the allowed amount for a replacement electrode/transducer exceeds the applicable dollar threshold in the member contract.

    • HCPCS A4555: Electrode/transducer for use with an electrical stimulation device used for cancer treatment, replacement only.
    Prior Authorization

    Prior Approval Required for Cancer-Treatment Device

    Prior approval is required for HCPCS E0766, the electrical stimulation device used for cancer treatment, including all accessories.

    • HCPCS E0766: Electrical stimulation device used for cancer treatment, includes all accessories, any type.
    Prior Authorization

    Therapy Overview

    Tumor treating fields therapy is a noninvasive treatment technology delivered on an outpatient basis and at home using electrical fields. The policy focuses on its use for central nervous system cancers, particularly glioblastoma and selected anaplastic gliomas. Initial instruction is provided so that patients can reapply the transducer arrays at home. Coverage is limited to the situations specified in the policy; therapy is considered investigational for all other indications.

    Key Terms

    Tumor treating fields (TTF) therapy
    TechnologyA noninvasive technology intended to treat certain cancers using electrical fields.
    Delivery settingDelivered on an outpatient basis and at home.
    Policy-described usesIntended to treat glioblastoma, malignant pleural mesothelioma, and non-small cell lung cancer.
    Glioblastoma multiforme (GBM)
    AbbreviationGlioblastoma multiforme (GBM).
    Clinical descriptionThe most common and deadly malignant brain tumor.
    Prognosis and quality of life
    Policy Summary
    PayerBlue Cross Blue Shield of Vermont
    PolicyTumor Treatment Fields for CNS Cancers
    Policy CodePolicy 1.01.VT29
    Change TypeAdministrative/reference update
    Effective DateFeb 1, 2027
    Last ReviewOct 1, 2026
    Next Review DateSep 1, 2027
    Key ActionSubmit a complete authorization request supporting the applicable medical-necessity criteria before requesting coverage.
    SourceLink
    On This Page
    When Tumor Treating Fields May Be CoveredTreatment Setting CriteriaBilling and CodingAuthorization and Administrative RequirementsTherapy OverviewKey Terms

    Plan-Specific Authorization

    Authorization requirements vary by plan. Obtain an approved referral authorization for New England Health Plan (NEHP) members and prior approval for Access Blue New England (ABNE) members.

    • NEHP: approved referral authorization required.
    • ABNE: prior approval required.

    Unsupported block type: documentation claims?

    Unsupported block type: info

    Unsupported block type: denial_risk

    Documentation Required

    Complete the Authorization Request

    Incomplete authorization requests may delay the decision while missing information is obtained. Ensure the request is complete and addresses the applicable policy guidelines before submission.

    • Include all required clinical documentation and information supporting medical necessity.
    Denial Risk

    Audit Noncompliance May Lead to Recoupment

    Identified noncompliance with authorization, documentation, or other policy requirements may result in recoupment of noncompliant payments.

    • Confirm required authorization and benefit verification before billing or providing the service.
    Associated with a very poor prognosis and low quality of life during treatment.